Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

Reproductive BioMedicine Online

Volumn 9, Issue 5, 2004, Pages 505-510

  Orio Jr , Francesco ^a   Palomba, Stefano ^b   Cascella, Teresa ^a   Tauchmanovà, Libuse ^a   Nardo, Luciano G ^c   Di Biase, Sebastiano ^d   Labella, Donato ^d   Russo, Tiziana ^b   Savastano, Silvia ^e   Tolino, Achille ^a   Zullo, Fulvio ^b   Colao, Annamaria ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c KINGSTON HOSPITAL   (United Kingdom)

^d 'MeriGen' Molec Biology Laboratory   (Italy)

^e NONE

Author keywords

Cardiovascular risk; Insulin resistance; PAI 1 activity; Polycystic ovary syndrome (PCOS)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HOMEOSTASIS; HUMAN; HYPERTENSION; MEDICAL ASSESSMENT; METABOLIC PARAMETERS; MORBIDITY; OBESITY; OVARY POLYCYSTIC DISEASE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STROKE;

EID: 8744223271     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61634-3     Document Type: Article

References (55)

1. Alessi MC, Juhan-Vague I, Kooistra T et al. 1988 Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thrombosis and Haemostasis 60, 491-494.
2. Alessi M-C, Gausseum P, Juhan-Vague I et al. 1990 The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; comparision with other methods. Fibrinolysis 4, 177-181.
3. Anfosso F, Chomiki N, Alessi MC et al. 1993 Plasminogen activator inhibitor 1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. Journal of Clinical Investigation 91, 2185-2193.
4. Anfosso F, Alessi MC, Nalbone G et al. 1995 Up regulated expression of plasminogen activator inhibitor-1 in Hep G2 cells; interrelationship between insulin and insulin-like growth factor 1. Thrombosis and Haemostasis 73, 268-274.
5. Atiomo WU, Fox R, Condon JE et al. 2000 Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clinical Endocrinology 52, 487-492.
6. Carmina E, Lobo RA 1999 Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. Journal of Clinical Endocrinology and Metabolism 84, 1897-1899.
7. Carmina E, Koyama T, Chang L et al. 1992 Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? American Journal of Obstetrics and Gynecology 167, 1807-1812.
8. Cibula D, Cifkova R, Fanta M et al. 2000 Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of polycystic ovary syndrome. Human Reproduction 22, 141-146.
9. Dawson S, Henney A 1992 The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 95, 105-117.
10. Diamantopoulos EJ, Andreadis EA, Vassilopoulos CV et al. 2003 Increased plasma plasminogen activator inhibitor-1 levels: a possible marker of hypertensive target organ damage. Clinical and Experimental Hypertension 25, 1-9.
11. Eliasson M, Asplund K, Evrin PE et al. 1994 Hyperinsulinemia predicts low tissue plasminogen activator activity in healthy population: The Northern Sweden MONICA Study. Metabolism 43, 1579-1586.
12. Elting MW, Korsen TJM, Shoemaker J 2001 Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinemia, dyslipidemia and hypertension in ageing women with polycystic ovary sindrome. Clinical Endocrinology 55, 767-776.
13. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM 2002 Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51, 1131-1137.
14. Folsom AR, Qamhieh HT, Wing RR et al. 1993 Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arteriosclerosis and Thrombosis 13, 162-169.
15. Glueck CJ, Rorick MH, Schmerler M et al. 1995 Hypofibrinolytic and atherogenic risk factors for stroke. Journal of Laboratory and Clinical Medicine 125, 319-325.
16. Haffner SM, D'Agostino Jr R, Mykkanen L et al. 1999 Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22, 562-568.
17. Hamsten A, Wiman B, de Faire U, Blomback M 1985 Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New England Journal of Medicine 313, 1557-1563.
18. Hamsten A, de Faire U, Walldius G et al. 1987 Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2, 3-9.
19. He G, Pedersen SB, Bruun JM et al. 2003 Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Hormone and Metabolic Research 35, 178-182.
20. Juhan-Vague I, Alessi MC 1997 PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thrombosis and Haemostasis 78, 656-660.
21. Juhan-Vague I, Thompson SG, Jeperson J 1993 Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arteriosclerosis and Thrombosis 13, 1865-1873.
22. Kelly CJ, Lyall H, Petrie JR et al. 2002 A specific elevation in tissue plasminogen antigen in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 87 3287-3290.
23. Kohler HP, Grant PJ 2000 Plasminogen-activator inhibitor type 1 and coronary artery disease. New England Journal of Medicine 342, 1792-1801.
24. Kruithof EKO 1988 Plasminogen activator inhibitor 1: biomedical, biological and clinical aspects. Fibrinolysis 2, 59-70.
25. Landin K, Tengborn L, Smith U 1994 Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic euglicemic clamp in man. Thrombosis and Haemostasis 71, 783-787.
26. Legro RS 2001 Polycystic ovary syndrome: the new millenium. Molecular and Cellular Endocrinology 184, 87-93.
27. Loskutoff DJ, Samad F. 1998 The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arteriosclerosis, Thrombosis and Vascular Biology 18, 1-6.
28. Ma LJ, Mao SL, Taylor KL et al. 2004 Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53, 336-346.
29. Mansfield MW, Heywood DM, Grant PJ 1996 Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first degree relatives of patients with NIDDM. Circulation 94, 2171-2176.
30. Matthews DR, Hosken JP, Rudenski AS et al. 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419.
31. Mavri A, Alessi MC, Bastelica D et al. 2001 Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 44, 2025-2031.
32. Meade TW, Cooper JA, Chakrabarti R et al. 1996 Fibrinolityc activity and clotting factors in ischaemic heart disease in women. British Medical Journal 312, 1581.
33. Meigs JB, Mittleman MA, Nathan DM et al. 2000 Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. Journal of the American Medical Association 283 221-228.
34. Mertens I, Van der Planken M, Corthouts B et al. 2001 Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Hormone and Metabolic Research 33, 602-607.
35. Morley JE, Patrick P, Perry III HM 2002 Evaluation of assay available to measure free testosterone. Metabolism 5, 554-559.
36. Nestler JE, Jakubowicz DJ 1996 Decreases in ovarian cytochrome p450c17alpha activity and serum free testosterone after reduction ofinsulin secretion in polycystic ovary syndrome. New England Journal of Medicine 335, 617-623.
37. Nordt TK, Sawa H, Fujii S, Sobel BE 1995 Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91, 764-770.
38. Orio F Jr, Palomba S, Colao A et al. 2001 Growth hormone secretion after baclofen administration in different phases of menstrual cycle in healthy women. Hormone Research 155, 131-136.
39. Orio F Jr, Lucidi P, Palomba S et al. 2003a Circulating ghrelin concentrations in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 88, 942-945.
40. Orio F Jr, Palomba S, Di Biase S et al. 2003b Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 88, 673-679.
41. Orio F Jr, Palomba S, Spinelli L et al. 2004a The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. Journal of Clinical Endocrinology and Metabolism 89, 3696-3701.
42. Orio F Jr, Palomba S, Cascella T et al. 2004b Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 89, 4588-4593.
43. Pasquali R, Fabbri R, Venturoli S et al. 1986 Effect of weight loss and antiandrogenic theraphy on sex hormone blood levels and insulin resistance in obese women with polycystic ovaries. American Journal of Obstetrics and Gynecology 154, 139-144.
44. Potter van Loon BJ, Kluft C, Radder JK et al. 1993 The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42, 945-949.
45. Reaven GM 1994 Syndrome X: 6 years later. Journal of Internal Medicine 236, 13-22.
46. Sampson M, Kong C, Patel A et al. 1996 Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology 45, 623-629.
47. Shimomura I, Funahashi T, Takahashi K et al. 1996 Enhanced expression of PAI-1 in visceral fat: possible contribution to vascular disease in obesity. Nature Medicine 2, 800-803.
48. Sills ES, Drews CD, Perloe M et al. 2003 Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system. Gynecological Endocrinology 17, 231-237.
49. Solano MP, Perry AC, Wang X et al. 2003 Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women. International Journal of Obstetrics and Related Metabolic Disorders 27, 82-87.
50. Stief TW, Lenz P, Becker U, Heimburger N 1988 Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: a novel principle. Thrombosis Research 50 559-573.
51. Tsilchorozidou T, Overton C, Conway GS 2004 The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology 60, 1-17.
52. Vague P, Juhan-Vague I, Chaberv V et al. 1989 Fat distribution and plasminogen activator inhibitor activity in non diabetic women. Metabolism 38, 913-915.
53. Velazquez EM, Mendoza SG, Wanf P, Glueck CJ 1997 Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein α, and immunoreative insulin levels in patients with the polycystic ovary syndrome. Metabolism 46, 454-457.
54. Yarali H, Yildirir A, Aybar F et al. 2001 Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertility and Sterility 76, 511-516.
55. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach, In: Dunaif A, Givens JR, Haseltine F, Merriam GR (eds). Polycystic Ovary Syndrome. Blackwell Scientific Publications, Boston, MA, pp. 377-384.